Dose of adenoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: Preclinical consideration

Japanese Journal of Cancer Research

Volumn 93, Issue 6, 2002, Pages 706-715

  Nakamori, Mikihito ^a   Iwahashi, Makoto ^a   Ueda, Kentaro ^a   Tsunoda, Takuya ^a,b   Terasawa, Hiroshi ^a   Hamada, Hirofumi ^c,d   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER INSTITUTE   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenoviral vector; Combined gene therapy; Cytokine gene; Preclinical study; Suicide gene

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL ENZYME; CYTOKINE; CYTOSINE DEAMINASE; FLUCYTOSINE; INTERLEUKIN 2; ANTIMETABOLITE; DEAMINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CELL ASSAY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUBCUTANEOUS TISSUE TUMOR; SURVIVAL TIME; TUMOR CELL; VIRAL GENE THERAPY; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; GENE THERAPY; GENE TRANSFER; GENETICS; LIVER TUMOR; MALE; METABOLISM; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; TIME;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; ESCHERICHIA COLI; FEMALE; FLUCYTOSINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; INTERLEUKIN-2; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NUCLEOSIDE DEAMINASES; TIME FACTORS;

EID: 0036327585     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01310.x     Document Type: Article

References (44)

1. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
2. Cytokine gene therapy with interleukin-2 transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity
3. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2
4. Antitumor effects of interteukin-2 gene-modified fibroblasts in an orthotopic colon cancer model
5. Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene
6. Intraturmoral injection of an adenovirus expressing interleukin 2 induces an immunity in a murine breast cancer model
7. Complete recovery of mice from pre-established tumor by direct intraturmoral delivery of an adenovirus vector harboring the murine IL-2 gene
8. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo
9. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
10. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus mediated genetic transduction
11. Cancer vaccines: The interleukin 2 dosage effect
12. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine
13. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes gliorna cells to 5-fluorocytosine
14. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver
15. Combination gene therapy for liver metastasis of colon carcinoma in vivo
16. Combination gene therapy for oral cancer in a murine model
17. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs survival
18. A family of bistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model
19. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or 137-1
20. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
21. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line
22. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: Comparing the efficacy of cytosine dearninase and herpes simplex virus thymidine kinase
23. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine dearninase
24. Tumor expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor
25. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory
26. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice
27. The immune response elicited by mammary adenocarcinorna cells transduced with interferon-gamma and cytosine deaminase genes cures lung metastases by parental cells
28. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing full-length virus genome
29. Efficient selection for high-expression transfectants with a novel eukaryotic vector
30. A simple and efficient method for purification of infectious recombinant adenovirus
31. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR
32. Cancer gene therapy: Connecting basic research with clinical inquiry
33. Immune system in suicide gene therapy
34. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and Th1-like profile of intratumoral cytokine expression
35. Induction of potent natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
36. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
37. Lowest dose interleukin-2 immunotherapy
38. The IL-2/IL-2 receptor system: A current overview
39. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice
40. Cytosine deaminase/5-fluorocytosine based vaccination against liver tumors: Evidence of distant bystander effect
41. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants
42. Regional 'pro-drug' gene therapy: Intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic carcinoma
43. Chemosensitivity testing of highly purified fresh human tumour cells with the MTT calorimetric assay
44. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity